Calgenex

Calgenex was a San Francisco-based biotechnology company that specialized in the development of non-viral gene therapy and protein expression systems. The company's core technology focused on the systemic delivery of therapeutic genes and the optimization of protein production within the body. Calgenex's research was primarily directed toward oncology and inflammatory disease applications, utilizing proprietary vectors for high-level gene expression. In April 1999, the company was acquired by Megabios Corporation for approximately $12 million in stock. Following the acquisition, Megabios merged with GeneMedicine to form Valentis, integrating Calgenex's delivery technologies into their broader gene therapy portfolio.